Severe Asthma
Conditions
Keywords
eosinophilic asthma, severe asthma, prevalence, phenotype, atopic phenotype, eosinophilic phenotype
Brief summary
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.
Detailed description
To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Patients must fulfil all of the following inclusion criteria to be included in the study: * Male or female patient, aged 12 years or older by the time of study entry * Patient visiting a participating center for a routine clinical appointment * Patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit * Diagnosis of severe asthma for at least one year as defined by: * Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma * Patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry.
Exclusion criteria
* Patients with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory condition beyond severe asthma * An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study Patients who are currently under a biologic therapy to treat their severe asthma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood Eosinophil count | There is only one study visit. During that study visit the sample will be collected | The level of eosinophils in the blood will be assessed from this blood sample and reported |
| Total serum IgE | There is only one study visit. during that visit the sample will be collected | Total serum IgE will be assessed from this blood sample and reported |
Countries
Argentina, Chile, Colombia, Costa Rica, Mexico, Saudi Arabia
Outcome results
None listed